These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 12914611)

  • 1. Class I or class III agents for atrial fibrillation: are asking the right question?
    Pacifico A; Henry PD
    Pacing Clin Electrophysiol; 2003 Jul; 26(7 Pt 2):1613-9. PubMed ID: 12914611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic management of atrial fibrillation: current therapeutic strategies.
    Lévy S
    Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN; Mody FV; Lopez B; Sarma JS
    Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches for pharmacological management of atrial fibrillation.
    Ehrlich JR; Nattel S
    Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic management of atrial fibrillation: established and emerging options.
    Kalus JS
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation.
    Singla S; Karam P; Deshmukh AJ; Mehta J; Paydak H
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):12-20. PubMed ID: 21335483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological approaches in the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Delpón E
    Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation.
    Kosior D; Opolski G; Torbicki A
    Med Sci Monit; 2001; 7(1):68-73. PubMed ID: 11208496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.
    Crijns HJ
    Drugs; 2005; 65(12):1651-67. PubMed ID: 16060699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F; Candinas R; Frielingsdorf J
    Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dronedarone for the treatment of atrial fibrillation and atrial flutter.
    Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.
    Nattel S; Khairy P; Roy D; Thibault B; Guerra P; Talajic M; Dubuc M
    Drugs; 2002; 62(16):2377-97. PubMed ID: 12396229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
    Wang J; Feng J; Nattel S
    Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.
    Bonora A; Turcato G; Franchi E; Taioli G; Dilda A; Zerman G; Maccagnani A; Pistorelli C; Olivieri O
    Intern Emerg Med; 2017 Sep; 12(6):853-859. PubMed ID: 27384766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Problems with anti-arrhythmia therapy in atrial fibrillation].
    Breithardt G; Kottkamp H; Haverkamp W; Hindricks G; Fetsch T; Borggrefe M
    Z Kardiol; 1994; 83 Suppl 5():63-9. PubMed ID: 7846947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.